Loading...
research article
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
2007
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we examined whether better use of existing drugs could shorten the duration of treatment. Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens.
Type
research article
Authors
Rosenthal, Ian M.
•
•
Williams, Kathy N.
•
Peloquin, Charles A.
•
Tyagi, Sandeep
•
Vernon, Andrew A.
•
Bishai, William R.
•
Chaisson, Richard E.
•
Grosset, Jacques H.
•
Nuermberger, Eric L.
Publication date
2007
Published in
Volume
4
Issue
12
Article Number
e344
Peer reviewed
NON-REVIEWED
EPFL units
Available on Infoscience
April 27, 2012
Use this identifier to reference this record